The Triterpenoid Betulin Protects against the Neuromuscular Effects of Bothrops jararacussu Snake Venom In Vivo.
Miriéle Cristina Ferraz,Jhones Luiz de Oliveira,Joel Reis de Oliveira Junior,José Carlos Cogo,Márcio Galdino dos Santos,Luiz Madaleno Franco,Pilar Puebla,Helena Onishi Ferraz,Humberto Gomes Ferraz,Marisa Maria Teixeira da Rocha,Stephen Hyslop,Arturo San Feliciano,Yoko Oshima-Franco +12 more
TLDR
Results indicate that betulin given i.p. has a similar efficacy in attenuating the neuromuscular effects of B. jararacussu venom in vivo and could be a useful complementary measure to antivenom therapy for treating snakebite.Abstract:
We confirmed the ability of the triterpenoid betulin to protect against neurotoxicity caused by Bothrops jararacussu snake venom in vitro in mouse isolated phrenic nerve-diaphragm (PND) preparations and examined its capability of in vivo protection using the rat external popliteal/sciatic nerve-tibialis anterior (EPSTA) preparation. Venom caused complete, irreversible blockade in PND (40 μg/mL), but only partial blockade (~30%) in EPSTA (3.6 mg/kg, i.m.) after 120 min. In PND, preincubation of venom with commercial bothropic antivenom (CBA) attenuated the venom-induced blockade, and, in EPSTA, CBA given i.v. 15 min after venom also attenuated the blockade (by ~70% in both preparations). Preincubation of venom with betulin (200 μg/mL) markedly attenuated the venom-induced blockade in PND; similarly, a single dose of betulin (20 mg, i.p., 15 min after venom) virtually abolished the venom-induced decrease in contractility. Plasma creatine kinase activity was significantly elevated 120 min after venom injection in the EPSTA but was attenuated by CBA and betulin. These results indicate that betulin given i.p. has a similar efficacy as CBA given i.v. in attenuating the neuromuscular effects of B. jararacussu venom in vivo and could be a useful complementary measure to antivenom therapy for treating snakebite.read more
Citations
More filters
Journal ArticleDOI
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations
Lucy Webster,Derek Groskreutz,Anna Grinbergs-Saull,Robert Howard,John T. O'Brien,Gail Mountain,Sube Banerjee,Bob Woods,Robert Perneczky,Robert Perneczky,Robert Perneczky,Louise Lafortune,Charlotte A. Roberts,Jenny McCleery,James Pickett,Frances Bunn,David Challis,Georgina Charlesworth,Katie Featherstone,Chris Fox,Claire Goodman,Roy W. Jones,Sarah E Lamb,Esme Moniz-Cook,Justine Schneider,Sasha Shepperd,Claire Surr,Jo Thompson-Coon,Clive Ballard,Carol Brayne,Alistair Burns,Linda Clare,Peter Garrard,Patrick G. Kehoe,Peter Passmore,Clive Holmes,Ian Maidment,Louise Robinson,Gill Livingston,Gill Livingston +39 more
TL;DR: This is the first review to identify the 81 outcome measures the research community uses for disease-modifying trials in mild-to-moderate dementia, and recommended core outcomes were cognition as the fundamental deficit in dementia and to indicate disease modification, serial structural MRIs.
Journal ArticleDOI
Biological Properties and Therapeutic Applications of Propolis
TL;DR: The biological properties of propolis and some therapeutic applications are discussed, and the effects of common compounds found in the samples from all over the world are explored in an attempt to standardize the research on propoli and to obtain new drugs.
Journal ArticleDOI
Lead Phytochemicals for Anticancer Drug Development.
TL;DR: Lead phytochemicals with their action mechanisms on nuclear and cellular factors involved in carcinogenesis and druggability parameters and clinical development of anticancer phytomolecules have been discussed.
Journal ArticleDOI
Why people use herbal medicine: insights from a focus-group study in Germany
TL;DR: The finding that dissatisfaction with conventional medicine was the most important reason for a preferred use of herbal medicine, government bodies, doctors, and pharmaceutical companies need to be aware of this problem and should aim to establish a certain level of awareness among users concerning this issue.
Journal ArticleDOI
The Mechanisms of Action of Curcumin in Alzheimer's Disease.
Mengxi Tang,Changiz Taghibiglou +1 more
TL;DR: In conclusion, curcumin has the potential to be more efficacious than current treatments, however, its usefulness as a therapeutic agent may be hindered by its low bioavailability.
References
More filters
Evidence-based Complementary and Alternative Medicine
TL;DR: A literature search yielded 24 randomized controlled trials (RCTs) of pediatric MT, defined as the manual manipulation of soft tissue intended to promote health and well-being in recipients between 2 and 19 years of age as discussed by the authors.
Book
Poly(ethylene glycol) chemistry : biotechnical and biomedical applications
TL;DR: PEG Derivatized Ligands with Hydrophobic and Immunological Specificity and Preparation and Properties of Monomethoxypoly(Ethylene Glycol)Modified Enzymes for Therapeutic Applications.